Back to Search
Start Over
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – An EAACI‐ARIA Position Paper
- Source :
- Allergy
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Coronavirus disease 2019 (COVID-19) vaccine BNT162b2 received approval and within the first few days of public vaccination several severe anaphylaxis cases occurred. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and concerns raised for severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerges. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as the exclusion of all these patients from vaccination may have a significant impact on reaching the goal of population immunity. Health care practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognise and treat anaphylaxis properly with the ability to administer adrenaline. A mandatory observation period after vaccine administration of at least 15 minutes for all individuals should be followed. The current data has not shown any higher risk for patients suffering from allergic rhinitis or asthma and this message should be clearly stated by physicians to give our patients trust. The benefit of the vaccination clearly outweighs the risk of severe COVID-19 development including the more than 30% of the population suffering from allergic diseases.
- Subjects :
- 0301 basic medicine
Allergy
medicine.medical_specialty
COVID-19 Vaccines
Immunology
Population
610 Medicine & health
Herd immunity
03 medical and health sciences
0302 clinical medicine
10183 Swiss Institute of Allergy and Asthma Research
medicine
Humans
Immunology and Allergy
Medical history
education
Intensive care medicine
Adverse effect
BNT162 Vaccine
Asthma
Vaccines
2403 Immunology
education.field_of_study
SARS-CoV-2
business.industry
COVID-19
medicine.disease
Vaccination
030104 developmental biology
030228 respiratory system
2723 Immunology and Allergy
business
Anaphylaxis
Subjects
Details
- ISSN :
- 13989995 and 01054538
- Volume :
- 76
- Database :
- OpenAIRE
- Journal :
- Allergy
- Accession number :
- edsair.doi.dedup.....c4401b0904a93464c2da63cf19aa1ca5
- Full Text :
- https://doi.org/10.1111/all.14726